|
|
Volumn 30, Issue 5, 2012, Pages 375-376
|
|
Stromedix acquisition signals growing interest in fibrosis.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ALPHAVBETA6 INTEGRIN;
INTEGRIN;
MONOCLONAL ANTIBODY;
TUMOR ANTIGEN;
BIOTECHNOLOGY;
COMMERCIAL PHENOMENA;
DRUG EFFECT;
ECONOMICS;
EUROPE;
FIBROSIS;
HUMAN;
IMMUNOLOGY;
LUNG;
MEDICAL RESEARCH;
NOTE;
UNITED STATES;
ANTIBODIES, MONOCLONAL;
ANTIGENS, NEOPLASM;
BIOMEDICAL RESEARCH;
BIOTECHNOLOGY;
COMMERCE;
EUROPE;
FIBROSIS;
HUMANS;
INTEGRINS;
LUNG;
UNITED STATES;
|
|
EID: 84865692752
PISSN: None
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt0512-375 Document Type: Note |
|
Times cited : (7)
|
|
References (0)
|
